Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer

NCT05573373 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
EGF-R Positive Non-Small Cell Lung Cancer

Interventions

DRUG: Parimparib
DRUG: Chemotherapy drug
DRUG: Targeted Therapy Agent

Sponsor

Affiliated Hospital of Jiangnan University